Allgens(SH:688613)2022-04-27 16:00Financial Performance - In 2021, the company's operating revenue reached ¥236,063,153.91, representing a year-on-year increase of 28.46%[19]. - The net profit attributable to shareholders was ¥120,782,633.54, a growth of 35.80% compared to the previous year[19]. - The net profit after deducting non-recurring gains and losses was ¥97,465,242.08, reflecting an 18.34% increase year-on-year[19]. - The net cash flow from operating activities increased by 52.89% to ¥129,764,601.13, driven by higher sales revenue and significant cash collections[22]. - Total assets grew by 77.17% to ¥1,426,076,280.49, primarily due to increased sales and fundraising from the public offering[22]. - Basic earnings per share were ¥1.01, up 13.48% from ¥0.89 in 2020[20]. - The weighted average return on equity increased to 17.19%, up 1.79 percentage points from the previous year[21]. - The company achieved total revenue of CNY 236.06 million in 2021, representing a year-on-year growth of 28.46%[89]. - Net profit attributable to shareholders reached CNY 120.78 million, with a year-on-year increase of 35.80%[89]. Dividend Policy - The proposed cash dividend is 2.72 RMB per 10 shares, totaling approximately 36.27 million RMB, which represents 30.03% of the net profit attributable to shareholders[5]. - The company does not plan to issue bonus shares or convert capital reserves into share capital, with remaining undistributed profits carried forward to the next year[5]. - The company has a cash dividend policy that prioritizes cash distributions, aiming for a minimum of 30% of the average distributable profit over the last three years[151]. - In the event of significant investment plans, the company will ensure that cash dividends do not exceed 30% of the latest audited net assets[152]. - The company has not made any adjustments to its established cash dividend policy during the reporting period[156]. Research and Development - The company's R&D expenditure as a percentage of operating revenue rose to 14.08%, an increase of 5.37 percentage points from the previous year[21]. - The company applied for 9 invention patents and obtained 7 in 2021, enhancing its intellectual property portfolio[33]. - The company has increased its R&D investment by 107.59% year-on-year, totaling approximately 33.23 million CNY, which represents 14.08% of its operating revenue[65][66]. - The company holds a total of 45 invention patents, with 7 new patents granted during the reporting period[62][63]. - The company is involved in a national key R&D project focused on new generation biomimetic collagen implants, which is progressing smoothly[62]. - The company has established a multidisciplinary R&D team focusing on high-end biomedical materials, undertaking numerous national and provincial major R&D projects, which reflects its technical level and management capabilities[172]. Market Expansion and Sales Strategy - The company plans to continue expanding its market presence and enhancing brand recognition through various marketing activities[22]. - The company added 60 new agents and developed nearly 100 new hospitals, increasing the number of terminal hospitals by approximately 25%[31]. - The company is focusing on expanding its product line and business areas by developing various high-performance regenerative medical materials[50]. - The company is advancing multiple high-end regenerative medicine product research projects, including collagen sponge and collagen-guided tissue regeneration membranes, which are currently in clinical trial stages[40]. - The company is focusing on expanding its market presence in the EU and the US, particularly in spinal repair technologies[69]. - The company plans to enter the European market in 2022, targeting a revenue contribution of $100 million in the first year[127]. Governance and Management - The management has confirmed the authenticity, accuracy, and completeness of the financial report[5]. - The governance structure includes a clear division of responsibilities among the shareholders' meeting, board of directors, supervisory board, and management[120]. - The company has established specialized committees under the board of directors to provide professional advice for major decisions[120]. - The company has implemented a comprehensive welfare system, including mandatory social insurance and supplementary medical funds[148]. - The company has established a performance evaluation mechanism for senior management, linking their compensation to the achievement of annual operational goals[159]. Risks and Challenges - The company has not reported any significant risks that could materially affect its operations during the reporting period[4]. - The company faces risks related to product registration renewals, which could adversely affect its operations if policies change[79]. - The company’s gross margin is influenced by various factors, including sales price changes and production costs, posing a risk of decline[81]. - The company’s subsidiaries have not yet achieved profitability, indicating potential short-term financial risks[81]. - The company is subject to industry risks, including potential changes in healthcare policies that could impact its operational strategies[82]. Environmental and Social Responsibility - The company emphasizes the importance of ESG (Environmental, Social, and Governance) as a cornerstone for sustainable development and has contributed 3 million RMB to Tsinghua University for scholarships[162]. - The company has implemented a comprehensive environmental protection system and conducts training on environmental management[167]. - The company does not fall under the category of key pollutant discharge units and has not faced any administrative penalties for environmental issues during the reporting period[164]. - The company is committed to optimizing processes to reduce resource consumption and improve efficiency in its production operations[165]. - The company has taken measures to reduce carbon emissions, including optimizing processes and improving the utilization of raw materials and equipment[169]. Employee and Talent Management - The company employed a total of 146 staff members, with 115 in the parent company and 33 in major subsidiaries[147]. - The employee composition includes 38 production staff, 47 sales personnel, 19 technical staff, 6 financial staff, and 36 administrative staff[147]. - The company has implemented a training plan that includes onboarding, skills enhancement, and both internal and external training resources[149]. - Total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to RMB 13.67 million[137]. - Total remuneration for core technical personnel at the end of the reporting period was RMB 4.50 million[137]. Product Development and Quality Assurance - The company has established a comprehensive quality management system certified by ISO 9001 and ISO 13485, ensuring that all products meet established quality standards[179]. - The company has not experienced any major product quality disputes in 2021, indicating a strong commitment to quality assurance[179]. - The company has implemented advanced energy-saving equipment in its production processes to reduce electricity consumption and optimize resource utilization[169]. - The company has established a robust mechanism for managing intellectual property, ensuring timely protection and response to market infringement[186]. Investor Relations and Communication - The company actively engages with investors through performance briefings and maintains a dedicated investor relations section on its website to enhance transparency and communication[183]. - The company emphasizes transparency in information disclosure, ensuring that all investors have equal access to company information through multiple communication channels[185]. - The company has developed an IR flagship store to facilitate multi-dimensional communication with retail investors[185]. - The company conducted various investor communication activities in 2021, including large public events and factory visits, to convey its long-term value and operational status accurately to investors[184].